エデサ・バイオテック
Edesa Biotech, Inc.
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q3 | -0.60 | $0 | -$3M |
| 2026 Q2 | -0.49 | $0 | -$2M |
| 2025 Q1 | -0.28 | $0 | -$2M |
| 2025 Q4 | -0.32 | $0 | -$2M |
| 2025 Q3 | -0.25 | $0 | -$2M |
| 2025 Q2 | -0.30 | $0 | -$2M |
| 2024 Q1 |
| -0.48 |
| $0 |
| -$2M |
| 2024 Q4 | -0.30 | $0 | -$967,039 |